Warning Letter — The Platinum Healthcare LLC
The FDA's Center for Drug Evaluation and Research issued a Warning Letter to The Platinum Healthcare LLC on October 1, 2026. the source text confirms the issuance but does not specify the exact nature of the violations.
The Platinum Healthcare LLC, as well as personnel involved in drug manufacturing, quality systems, and regulatory compliance at this organization.
Warning Letters from CDER typically indicate significant deviations from current Good Manufacturing Practice (cGMP) or other regulatory requirements. While the specific violations are not detailed in the provided excerpt, such letters generally require formal remediation and can lead to further enforcement actions if the cited issues are not adequately addressed.
Regulatory and QA departments should review the specific deficiencies cited in the full warning letter to ensure internal processes align with CDER expectations. Immediate attention should be given to any manufacturing or labeling practices that triggered the inspectional findings.
FDA Warning Letter issued to: The Platinum Healthcare LLC. 10/01/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/platinum-healthcare-llc-735147-10012026
Open in openFDA / FDA.gov